Dawn Velligan, PhD

Treatment Patterns From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia

OASIS was a 12-month observational study evaluating real-world outcomes of atypical long-acting injectable (aLAI) antipsychotics in patients with schizophrenia. Most patients initiated aL...

Dawn Velligan , PhD;

10/26/2023

Treatment Experiences of Individuals With Schizophrenia: Findings From an Online Survey

Background: This study examined experiences of patients living with schizophrenia with a history of oral antipsychotic medication (OAM) use.

Julia Carpenter-Conlin , MSW;

Leona Bessonova , PhD;

Jakob Bjorner , MD, PhD;

Dawn Velligan , PhD;

Michael Doane , PhD;

Martha Sajatovic , MD;

Stephen Maher , PhD;

Asia Sikora Kessler , PhD;

11/22/2019

Treatment Experiences of Individuals With Bipolar I Disorder: Findings From an Online Survey

Background: Oral antipsychotic medications (OAMs) are frequently prescribed to patients with bipolar I disorder (BD-1) for symptom control. A cross-sectional survey examined side effects ...

Julia Carpenter-Conlin , MSW;

Leona Bessonova , PhD;

Dawn Velligan , PhD;

Aaron Yarlas , PhD;

Martha Bayliss , MSc;

Nishtha Baranwal , MPH;

Kaitlin Rychlec , BS;

Michael Doane , PhD;

Martha Sajatovic , MD;

11/22/2019

A Comparison of Barriers and Drivers Between Prescribing and Non-Prescribing Psychiatric Care Providers Regarding Use of Digital Medication Adherence Platforms

Background: Tracking medication adherence through an ingestible event monitoring (IEM) sensor could benefit seriously mentally ill patients (SMI). Psychiatric providers may be reluctant t...

Jennifer Clerie , BS ;

Charles Ruetsch , PhD;

Heidi Waters , PhD, MBA;

Tigwa Davis , PhD;

Dawn Velligan , PhD;

Delbert Robinson , MD;

Chris Jaeger , MD, MBA;

William Carpenter , MD;

Joshua Liberman , PhD;

Felicia Forma , BSc;

11/22/2019

Barriers and Drivers of Adopting a Digital Medication Adherence Technology: Understanding the Factor Analysis Results

Background: A new digital medicine technology combining an ingestible event monitoring (IEM) sensor with an oral antipsychotic to track ingestion and adherence may be beneficial. However,...

William Carpenter , MD;

Joshua Liberman , PhD;

Felicia Forma , BSc;

Charles Ruetsch , PhD;

Jennifer Clerie , BS ;

Tigwa Davis , PhD;

Heidi Waters , PhD, MBA;

Dawn Velligan , PhD;

Delbert Robinson , MD;

Chris Jaeger , MD, MBA;

11/22/2019

The Frameworks to Support Adherence in Mental Health Working Group: Translating Science Into Action to Improve Patient Care

Shared decision making (SDM) involves healthcare providers and patients collaborating to make optimal healthcare decisions that align with patients’ goals and values. Patient decision aid...

Heidi Waters , PhD, MBA;

Dawn Velligan , PhD;

Felicia Forma , BSc;

Susan Bergeson ;

Martha Sajatovic , MD;

Jason Caplan , MD;

Michael Measom , MD;

Monica Oss , MS;

Michael Townsend , MA;

03/01/2019

Assessing Experiences, Attitudes, and Perceptions Associated With Treatment-Resistant Schizophrenia: Caregiver Focus Groups

Background: Treatment-resistant schizophrenia (TRS), defined as schizophrenia not responding to two trials of antipsychotics (APs) of adequate dose and duration, affects about one-third o...

Dana DiBenedetti , PhD;

Dawn Velligan , PhD;

Steven Kymes , PhD;

Anne-Marie Kelnaes , MA;

Thomas Brevig , MD, PharmD;

03/01/2019

Observational Study of Long-Acting Injectables in Schizophrenia (OASIS): Baseline Patient Demographics and Clinical Characteristics of Early Enrollees

Abstract: Background/Objective: Atypical long-acting injectable (aLAI) antipsychotics are efficacious treatments for schizophrenia; however, a deeper understanding of the real-world outco...

Dawn Velligan , PhD;

01/19/2023